Ignite Creation Date:
2025-12-25 @ 3:21 AM
Ignite Modification Date:
2025-12-26 @ 1:59 AM
Study NCT ID:
NCT06857305
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2025-03-04
First Post:
2025-02-26
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III Trial
Sponsor:
Ma Fei，MD
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-07-13
Start Date Type:
ACTUAL
Primary Completion Date:
2026-07-13
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-07-13
Completion Date Type:
ESTIMATED
First Submit Date:
2025-02-26
First Submit QC Date:
None
Study First Post Date:
2025-03-04
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-02-26
Last Update Post Date:
2025-03-04
Last Update Post Date Type:
ACTUAL